$Seelos Therapeutics(SEEL.US)$Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
$Seelos Therapeutics(SEEL.US)$3 MINUTES AGO, 8:15 AM EDT VIA PR NEWSWIRE SEEL SHARE NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. a company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in carin...
$Seelos Therapeutics(SEEL.US)$Seelos Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.
$Seelos Therapeutics(SEEL.US)$Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 1 MINUTE AGO, 8:00 AM EST Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk ...
$Seelos Therapeutics(SEEL.US)$Seelos Therapeutics Filed U.S. Patent Application #20240009113 : Treatment Of Protein Aggregation Myopathic And Neurodegenerative Diseases By Parenteral Administration Of Trehalose
$Seelos Therapeutics(SEEL.US)$Insiders bought enough shares to make the new support 1.38. Buy at 1.45. Sell at 2.90 for 100% profit. Borrow rate has tripled since Friday.
Insiders, including the CFO, may hold a bullish view of Seelos Therapeutics despite its recent losses and limited insider ownership, signaling a possible positive future outlook.
Seelos Therapeutics股票討論區
VIA PR NEWSWIRE
SEEL
SHARE
NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. a company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in carin...
1 MINUTE AGO, 8:00 AM EST
Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk ...
- float 7m
- Price 1.38
- Target 2
暫無評論